Zoledronic acid, or CGP 42’446, is a third-generation, nitrogen-containing bisphosphonate similar to ibandronic acid. It plays a role as a factor in maintaining bone thickness. Zoledronic acid is used to treat and prevent various types of osteoporosis, hypercalcemia from damage, multiple myeloma, bone metastases from malignant growth, and Paget’s disease of bone. Zoledronic acid was first photographed in writing in 1994. Zoledronic acid was approved for FDA approval on August 20, 2001. Zoledronic Acid Actavis is a modified form of Zoledronic Acid, but its uses are the same as above mentioned.
What is Zoledronic Acid Actavis?
Actavis is a drug that contains an acid zoledronic dynamic substance (4 mg). It can be accessed as a center to be turned into a veil solution to inject (drip) into a vein.
Zoledronic Actavis is a “traditional medicine”. This means that the zoledronic acid Actavis is similar to the “reference medicine” currently approved in the European Union (EU) called Zometa.
Is it suitable for osteoporosis and osteomyelitis?
The zoledronic acid Actavis can be used to prevent bone diseases in adults with most of the age-related bone diseases affecting the bones. These include osteoporosis, osteomalacia, fissures (bone fractures), spinal compression (when bone presses on the spinal cord), bone problems that require radiotherapy (radiation therapy) or a medical procedure, and hypercalcemia (high levels of calcium in the blood). Zoledronic corrosive Actavis may also be used to prevent and treat hypercalcemia caused by cancers.
The drug should be obtained with a PCP prescription.
How does Zoledronic Acid Actavis work?
Anhydrous third generation synthetic imidazole type of bisphosphonate analog of pyrophosphate with anti-adsorbent action. Zoledronate binds to the hydroxyapatite gem in the bone network and blocks farnesyl pyrophosphate (diphosphate) synthase, and in this way impedes protein prenylation within the mevalonate pathway. This leads to a deficiency of metabolites essential to the action of osteoclasts, which leads to the acceptance of apoptosis and in the long term, the demise of osteoclasts. By blocking bone resorption in which osteoclasts intervene, zoledronate reduces bone variability and stabilizes the bone network.
European Union approval
The European Commission granted a valid promotional license throughout the European Union for Zoledronic corrosive Actavis on 20 April 2012.
For more information about treatment with Zoledronic acid Actavis, read the package leaflet (also part of the EPAR) or contact your primary care provider or medication specialist.
Dosage of Zoledronic Acid Actavis
A typical portion of Zoledronic Acid Actavis is one mixture of 4 mg for a minimum of 15 minutes. When used to prevent bone entanglement, the mixture can be repeated every three to about a month, and patients should also take calcium supplements and nutrients D. A lower portion is suggested for patients with bone metastases (when the malignancy has spread in the depths) in case they have a gentler to direct problems with the kidneys. It is not recommended for patients with severe kidney problems.
Storage and care
After the first opening, Zoledronic Acid should be used immediately. If the arrangement is not used quickly, it should be placed in the refrigerator at 2°C – 8°C but not more than 24 hours
Side effects of Zoledronic Acid Actavis
Patients with excess dose may have renal asthenia, hypocalcemia, hypophosphatemia, and hypomagnesemia. The excess dose should be monitored by venous regulation of deficient particles.
Fever is the most common adverse effect associated with the erosive zoledronic implant. Influenza-like states, including fever, chills, bone pain, or the potential for joint pain and myalgia, were not frequently accounted for.
- Acute kidney injury
- Acquired Hyperostosis Syndrome
- Anemia [Source]